Press Releases and Events

IntraPace Announces First Commercial abiliti® System Patients

Procedures take place at Clinics in Spain and Germany

IntraPace, Inc. announced today that the first commercial patients in Europe have successfully received the abiliti system as a treatment for obesity. The patients were treated at the Clinica La Luz in Madrid, Spain, and Stadtkrankenhaus Schwabach, Germany.

This new device is built on the same proven technology used in millions of cardiac pacemakers and defibrillators each year. By enhancing the sense of fullness that a patient feels when they eat or drink, the abiliti system aids the patient in reducing the volume of food ingested. In addition, the abiliti system uses food detection and activity sensors to automatically monitor a person’s eating and exercise behavior. This information, which is critical to understanding patient behaviors and developing effective weight loss strategies, can be uploaded and viewed by the physician and patient.

“The abiliti System provides an innovative, patient-friendly option for people considering surgery to help control their weight. Successfully completing the first procedures with the product in Spain and Germany marks the beginning of our commercialization phase,” noted Chuck Brynelsen, President & CEO of IntraPace. “Interest in the product is building in other EU countries and we anticipate first patients in the UK in the near future.”

Following CE Mark in January 2011, the abiliti system is being commercialized via the following specialist obesity centers in Germany, Spain, the UK and Italy.


  • Stadtkrankenhaus Schwabach, Schwabach
  • Wolfart Klinik, Gräfelfing, Munich
  • Universitätsklinikum Wurzburg, Wurzburg
  • Chirurgische Klinik München-Bogenhausen, Munich


  • Clinica la Luz, Madrid


  • Nuffield Health Leeds Hospital
  • BMI Thornbury, Sheffield
  • BMI Albyn Hospital, Aberdeen
  • The National Obesity Surgery Centre, Sale
  • Spire Southampton Hospital


  • San Luca Ospedale, Torino

About the abiliti System
Following implantation via a simple minimally invasive surgical procedure, the abiliti system detects when a person eats or drinks and sends low level electrical impulses to the stomach. This stimulation is intended to help a person feel full before the stomach is actually full, causing them to eat less. As the anatomy of the stomach is not changed, clinical experience with the abiliti system has shown virtually none of the nausea and other side effects seen with gastric bypass surgery and gastric banding. Patients are not restricted in the types of food that they consume, but are encouraged to adopt a healthy diet and exercise program.

Further, this novel system automatically records when a patient eats, drinks and exercises. Using a simple wireless connection, patients and physicians can view the consumption and exercise data. Access to this important information provides an enormous benefit as it allows physicians and patients to understand patient behaviors and develop effective strategies for weight loss. Additionally, the system connects patients to a valuable social support network, support which research has demonstrated increases the effectiveness of weight loss programs.

About Obesity
Obesity is a worldwide epidemic that affects the health and lifestyles of hundreds of millions of people. The recent increase in obesity in most developed countries is staggering, and it cuts across all ages, ethnic groups, and socioeconomic classes. In 2005, the World Health Organization (WHO) estimated that 1.6 billion adults were overweight and at least 400 million were obese. By 2015, WHO projects that 2.3 billion adults worldwide will be overweight and more than 700 million clinically obese.

Increased weight raises the risk for numerous health problems including diabetes, hypertension (high blood pressure), heart disease, and stroke. For many obese people, diet and exercise plans have not allowed them to achieve sustained weight loss. For others, weight loss surgery has proven effective in helping them to lose substantial excess weight. However, the established surgical procedures impose lifestyle restrictions and have side effects and complication rates that leave many patients waiting for a better alternative.

About IntraPace
IntraPace was founded in 2001 to address an unmet need in weight loss surgery by developing a gentler solution for weight loss that incorporates essential components of behavior therapy. The abiliti system is intended to enable patients to achieve and sustain significant weight loss without the complications, lifestyle restrictions and substantial anatomical changes associated with the established weight loss surgeries.

Based in Mountain View, California, IntraPace is backed by premier investors, including Boston Scientific, CB Health Ventures, DFJ ePlanet Ventures, InCube Ventures, Johnson & Johnson Development Corp., L Capital Partners, Oxford Bioscience Partners, Toucan Capital Corp and Vulcan Capital.

The abiliti system has CE Mark in the European Union. It is not approved for sale in the United States. For more information, visit


Chuck Brynelsen, CEO
Tel: +1 (650) 316 4070

Sandy Greensmith
Tel: +41 (0)79 665 0486

Halsin Partners
Mike Sinclair
Tel: +44 (0)20 7318 2959

Return to Press Releases

The abiliti® system has received the CE Mark in the European Union. Not available in the United States.